Melioidosis, also called Whitmore’s disease, is an infectious disease that can infect humans or animals. The disease is caused by the bacterium Burkholderia pseudomallei. Melioidosis: The Most Neglected Tropical Disease Why is Burkholderia [Read more]
The National Institutes of Health (NIH) has selected Soligenix’s SGX942 (dusquetide) for the treatment of oral mucositis in head and neck cancer (HNC) patients as a Small Business Innovation Research/Small Business Technology [Read more]
In a new article published in The Lancet, experts review the current field of Ebola vaccine candidates and clinical trials and highlight key gaps in knowledge that need to be addressed by [Read more]
Vaccinations have begun in a first-in-human trial of an experimental Zika virus vaccine, the National Institute of Allergy and Infectious Diseases (NIAID) announced today. The experimental vaccine, known as rZIKV/D4Δ30-713, was developed [Read more]
Spero Therapeutics, Inc. today announced that it was awarded funding of $15.7 million, with the potential for up to an additional $28.5 million over 5 years, from the Biomedical Advanced Research and Development Authority (BARDA). The funding [Read more]
Soligenix, Inc. announced on July 9 that it has received notice of allowance for European and Canadian patent applications further extending protection around ThermoVax® including coverage of the Company’s ricin toxin vaccine, [Read more]
The Federal Bureau of Investigation (FBI) is seeking suppliers for anti-viral therapeutic Tamiflu to support is Pandemic Flu Preparedness Program stockpile. The FBI needs approximately 3,300 does of Tamiflu each year and [Read more]
By Jacqueline K. Olive, Peter J. Hotez, Ashish Damania, Melissa S. Nolan Summary Points A social movement of public health vaccine opposition has been growing in the United States in recent years; [Read more]
Characterized by the World Health Organization as a “neglected tropical disease,” leprosy (also known as Hansen’s disease) is caused by Mycobacterium leprae. Nearly a quarter of a million people are diagnosed with [Read more]
Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The first reported [Read more]
© 2018 STEMAR MEDIA